CA2371990A1 - Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale - Google Patents
Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale Download PDFInfo
- Publication number
- CA2371990A1 CA2371990A1 CA002371990A CA2371990A CA2371990A1 CA 2371990 A1 CA2371990 A1 CA 2371990A1 CA 002371990 A CA002371990 A CA 002371990A CA 2371990 A CA2371990 A CA 2371990A CA 2371990 A1 CA2371990 A1 CA 2371990A1
- Authority
- CA
- Canada
- Prior art keywords
- tumor
- oligonucleotides
- artificial sequence
- stabilized
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 97
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 230000000694 effects Effects 0.000 title abstract description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 109
- 210000004027 cell Anatomy 0.000 claims description 26
- 210000004881 tumor cell Anatomy 0.000 claims description 17
- 238000007920 subcutaneous administration Methods 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 5
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 229940104302 cytosine Drugs 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 208000000058 Anaplasia Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 67
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 56
- 108020004414 DNA Proteins 0.000 description 49
- 239000007924 injection Substances 0.000 description 35
- 238000002347 injection Methods 0.000 description 35
- 241001465754 Metazoa Species 0.000 description 34
- 239000011780 sodium chloride Substances 0.000 description 26
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 24
- 241000700159 Rattus Species 0.000 description 19
- 208000032612 Glial tumor Diseases 0.000 description 16
- 206010018338 Glioma Diseases 0.000 description 16
- 230000003308 immunostimulating effect Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 101000845188 Homo sapiens Tetratricopeptide repeat protein 4 Proteins 0.000 description 13
- 102100031279 Tetratricopeptide repeat protein 4 Human genes 0.000 description 13
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 13
- 150000004713 phosphodiesters Chemical class 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000011694 lewis rat Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000186366 Mycobacterium bovis Species 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 229960001438 immunostimulant agent Drugs 0.000 description 4
- 239000003022 immunostimulating agent Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- YMXFJTUQQVLJEN-UHFFFAOYSA-N pyrimidine Chemical compound C1=CN=CN=C1.C1=CN=CN=C1 YMXFJTUQQVLJEN-UHFFFAOYSA-N 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241001137251 Corvidae Species 0.000 description 2
- 241000288140 Gruiformes Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008094 contradictory effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000001936 parietal effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 206010037833 rales Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QFVKLKDEXOWFSL-UHFFFAOYSA-N 6-amino-5-bromo-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1Br QFVKLKDEXOWFSL-UHFFFAOYSA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR99/03433 | 1999-03-19 | ||
| FR9903433A FR2790955B1 (fr) | 1999-03-19 | 1999-03-19 | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| PCT/FR2000/000676 WO2000056342A2 (fr) | 1999-03-19 | 2000-03-17 | Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2371990A1 true CA2371990A1 (fr) | 2000-09-28 |
Family
ID=9543401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002371990A Abandoned CA2371990A1 (fr) | 1999-03-19 | 2000-03-17 | Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7700569B1 (https=) |
| EP (1) | EP1162982B9 (https=) |
| JP (1) | JP2002539265A (https=) |
| AT (1) | ATE288759T1 (https=) |
| AU (1) | AU3300600A (https=) |
| CA (1) | CA2371990A1 (https=) |
| DE (1) | DE60018050T2 (https=) |
| DK (1) | DK1162982T3 (https=) |
| ES (1) | ES2235839T3 (https=) |
| FR (1) | FR2790955B1 (https=) |
| PT (1) | PT1162982E (https=) |
| WO (1) | WO2000056342A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2711670B1 (fr) * | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| PT1077722E (pt) | 1998-05-22 | 2006-12-29 | Coley Pharm Group Inc | Produtos e composições para utilização na indução da imunidade mucosal |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| WO2000048630A1 (en) | 1999-02-17 | 2000-08-24 | Csl Limited | Immunogenic complexes and methods relating thereto |
| FR2790955B1 (fr) * | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| IL160157A0 (en) | 2001-08-17 | 2004-07-25 | Coley Pharm Group Inc | Combination motif immune stimulation oligonucleotides with improved activity |
| US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| PT2241325E (pt) | 2002-10-29 | 2012-04-12 | Coley Pharm Gmbh | Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c |
| US10100316B2 (en) * | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
| EP1578954A4 (en) | 2002-12-11 | 2010-08-11 | Coley Pharm Group Inc | 5'-CPG NUCLEIC ACIDS AND USE METHOD |
| EP1675614A2 (en) * | 2003-10-11 | 2006-07-05 | Inex Pharmaceuticals Corp. | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| WO2006010838A2 (fr) * | 2004-06-25 | 2006-02-02 | Institut Gustave Roussy | Produits contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant |
| EP1649859A1 (fr) * | 2004-10-22 | 2006-04-26 | Institut Gustave Roussy | Produits pharmaceutiques contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant sous forme d'oligodésoxynucléotide |
| MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| AU2006220835B2 (en) | 2005-03-04 | 2012-01-19 | Dynavax Technologies Corporation | Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients |
| CA2723672C (en) * | 2007-05-11 | 2019-09-03 | Adynxx, Inc. | Gene expression and pain |
| FR2975600B1 (fr) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
| US20130210896A1 (en) * | 2011-11-09 | 2013-08-15 | City Of Hope | Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System |
| EP3511022A1 (en) | 2012-05-10 | 2019-07-17 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
| JP6705807B2 (ja) | 2014-08-15 | 2020-06-03 | エーダイニクス インコーポレイテッド | 疼痛を治療するためのオリゴヌクレオチドデコイ |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| KR20240113607A (ko) | 2017-06-21 | 2024-07-22 | 트랜스진 | 개인 맞춤형 백신 |
| JP2021516957A (ja) | 2018-03-07 | 2021-07-15 | トランジェーヌＴｒａｎｓｇｅｎｅ | パラポックスウイルスベクター |
| JP7625521B2 (ja) | 2018-12-28 | 2025-02-03 | トランスジーン | ｍ２欠陥ポックスウイルス |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5734033A (en) * | 1988-12-22 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Antisense oligonucleotides inhibiting human bcl-2 gene expression |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| JPH04352724A (ja) * | 1990-07-27 | 1992-12-07 | Mitsui Toatsu Chem Inc | 免疫調節型治療剤 |
| EP0468520A3 (en) * | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| AU2580892A (en) | 1991-09-05 | 1993-04-05 | Isis Pharmaceuticals, Inc. | Determination of oligonucleotides for therapeutics, diagnostics and research reagents |
| ATE235549T1 (de) | 1993-04-30 | 2003-04-15 | Biognostik Ges | Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2 |
| EP0708829B8 (en) * | 1993-07-10 | 2004-07-21 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms |
| US6001982A (en) | 1993-07-29 | 1999-12-14 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
| EP1584682B1 (en) * | 1993-09-20 | 2009-07-15 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| ATE509102T1 (de) * | 1994-07-15 | 2011-05-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| US6160109A (en) | 1995-10-20 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Preparation of phosphorothioate and boranophosphate oligomers |
| US6280978B1 (en) * | 1995-12-15 | 2001-08-28 | Intronn Holdings, Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| EP0914324B1 (en) * | 1996-05-22 | 2001-12-05 | McGILL UNIVERSITY | Specific inhibitors of dna methyltransferase enzyme |
| EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| US5965420A (en) * | 1997-03-05 | 1999-10-12 | Smithkline Beecham Corporation | Human protein kinases hYAK3 |
| WO1998055495A2 (en) * | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| ATE294388T1 (de) * | 1997-08-29 | 2005-05-15 | Univ California | Modulatoren der cytosin-5-methyl-transferase und verfahren zu ihrer verwendung |
| DK1009413T3 (da) * | 1997-09-05 | 2007-06-11 | Univ California | Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma |
| US5874416A (en) * | 1997-11-07 | 1999-02-23 | Sheikhnejad; Gholamreza | RAS antisense inhibition |
| US6060310A (en) | 1997-11-24 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Transcription factor decoy and tumor growth inhibitor |
| US6020475A (en) | 1998-02-10 | 2000-02-01 | Isis Pharmeuticals, Inc. | Process for the synthesis of oligomeric compounds |
| ATE356630T1 (de) | 1998-04-03 | 2007-04-15 | Univ Iowa Res Found | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
| US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| US6166239A (en) | 1998-09-04 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligonucleotide protecting groups |
| WO2000016804A1 (en) | 1998-09-18 | 2000-03-30 | Dynavax Technologies Corporation | METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
| US6069243A (en) | 1998-10-06 | 2000-05-30 | Isis Pharmaceuticals, Inc. | Process for oligonucleotide synthesis |
| EP1117433A1 (en) | 1998-10-09 | 2001-07-25 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
| US6169177B1 (en) | 1998-11-06 | 2001-01-02 | Isis Pharmaceuticals, Inc. | Processes for the synthesis of oligomeric compounds |
| US6121437A (en) | 1999-03-16 | 2000-09-19 | Isis Pharmaceuticals, Inc. | Phosphate and thiophosphate protecting groups |
| FR2790955B1 (fr) * | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| AU4237300A (en) | 1999-04-19 | 2000-11-02 | Engelhard Corporation | Catalyst composition comprising ceria and a platinum group metal |
| WO2001051061A1 (en) * | 2000-01-14 | 2001-07-19 | Intrabiotics Pharmaceuticals, Inc. | Derivatives of polyene macrolides and preparation and use thereof |
-
1999
- 1999-03-19 FR FR9903433A patent/FR2790955B1/fr not_active Expired - Fee Related
-
2000
- 2000-03-17 WO PCT/FR2000/000676 patent/WO2000056342A2/fr not_active Ceased
- 2000-03-17 DK DK00910993T patent/DK1162982T3/da active
- 2000-03-17 EP EP00910993A patent/EP1162982B9/fr not_active Expired - Lifetime
- 2000-03-17 US US09/937,057 patent/US7700569B1/en not_active Expired - Fee Related
- 2000-03-17 PT PT00910993T patent/PT1162982E/pt unknown
- 2000-03-17 DE DE60018050T patent/DE60018050T2/de not_active Expired - Lifetime
- 2000-03-17 AU AU33006/00A patent/AU3300600A/en not_active Abandoned
- 2000-03-17 ES ES00910993T patent/ES2235839T3/es not_active Expired - Lifetime
- 2000-03-17 CA CA002371990A patent/CA2371990A1/fr not_active Abandoned
- 2000-03-17 JP JP2000606246A patent/JP2002539265A/ja active Pending
- 2000-03-17 AT AT00910993T patent/ATE288759T1/de active
-
2001
- 2001-09-28 US US09/967,881 patent/US7108844B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2235839T3 (es) | 2005-07-16 |
| US7108844B2 (en) | 2006-09-19 |
| ATE288759T1 (de) | 2005-02-15 |
| FR2790955A1 (fr) | 2000-09-22 |
| WO2000056342A3 (fr) | 2001-07-26 |
| FR2790955B1 (fr) | 2003-01-17 |
| EP1162982B1 (fr) | 2005-02-09 |
| JP2002539265A (ja) | 2002-11-19 |
| DE60018050D1 (de) | 2005-03-17 |
| US20020192184A1 (en) | 2002-12-19 |
| DE60018050T2 (de) | 2006-02-23 |
| EP1162982B9 (fr) | 2005-07-06 |
| AU3300600A (en) | 2000-10-09 |
| PT1162982E (pt) | 2005-05-31 |
| US7700569B1 (en) | 2010-04-20 |
| DK1162982T3 (da) | 2005-06-13 |
| EP1162982A2 (fr) | 2001-12-19 |
| WO2000056342A2 (fr) | 2000-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2371990A1 (fr) | Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale | |
| JP6525455B2 (ja) | 免疫賦活活性を有するオリゴヌクレオチド含有複合体及びその用途 | |
| US7208478B2 (en) | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates | |
| Carpentier et al. | CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma | |
| EP1326636B1 (fr) | Composition vaccinale | |
| US7851454B2 (en) | Short immunomodulatory oligonucleotides | |
| JP7419268B2 (ja) | 変異ｋｒａｓ配列及び脂質を含む化合物並びにその使用 | |
| CN109069527B (zh) | 纳米颗粒、控释剂型和用于递送免疫治疗剂的方法 | |
| AU2009302468A1 (en) | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto | |
| ES3035198T3 (en) | Cpg amphiphiles and uses thereof | |
| EP1750707A1 (fr) | Composition immunostimulante comprenant au moins un agoniste des recepteurs toll-like 7 ou du recepteur toll-like 8 et un agoniste du recepteur toll-like 4 | |
| US9919058B2 (en) | Polyketal particles including a CpG oligodeoxynucleotide for the treatment of lung cancer | |
| JP6698069B2 (ja) | 免疫賦活活性を有するＣｐＧスペーサーオリゴヌクレオチド含有複合体及びその用途 | |
| WO2020247724A1 (en) | Dna nanostructure-based vaccines | |
| US12611455B2 (en) | DNA nanostructure-based vaccines | |
| WO2006010838A2 (fr) | Produits contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant | |
| RU2823677C2 (ru) | Cpg амфифилы и их применения | |
| JP2026067877A (ja) | 変異ｋｒａｓ配列及び脂質を含む化合物並びにその使用 | |
| HK40043265B (zh) | 包含突变kras序列和脂质的化合物及其用途 | |
| HK40045177A (en) | Cpg amphiphiles and uses thereof | |
| HK40045177B (en) | Cpg amphiphiles and uses thereof | |
| HK40002256B (en) | Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent | |
| EP1649859A1 (fr) | Produits pharmaceutiques contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant sous forme d'oligodésoxynucléotide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |